News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cardiome Pharma Corp. (COM.TO) Accepts the Transfer of Sponsorship of U.S. and Canadian Vernakalant IV and Oral Regulatory Filings From Merck & Co., Inc. (MRK)



5/2/2013 11:26:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

VANCOUVER, May 2, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced completion of the transfer of sponsorship of the U.S. Investigational New Drug Applications for vernakalant intravenous (IV) and oral, and the transfer of the U.S. New Drug Application for vernakalant IV from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck). In addition to the transfer of the U.S. regulatory filings, Merck Canada Inc., a subsidiary of Merck, transferred its sponsorship of all vernakalant Canadian Clinical Trial Applications to Cardiome.

Help employers find you! Check out all the jobs and post your resume.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES